CN103119059A - 针对人抗苗勒管激素ii型受体的新的突变型人源化12g4抗体及其片段 - Google Patents
针对人抗苗勒管激素ii型受体的新的突变型人源化12g4抗体及其片段 Download PDFInfo
- Publication number
- CN103119059A CN103119059A CN2011800322118A CN201180032211A CN103119059A CN 103119059 A CN103119059 A CN 103119059A CN 2011800322118 A CN2011800322118 A CN 2011800322118A CN 201180032211 A CN201180032211 A CN 201180032211A CN 103119059 A CN103119059 A CN 103119059A
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- antibody
- light chain
- following
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
Abstract
Description
缔合常数 | 解离常数 | 平衡亲和常数 | |
人源化12G4 | 1.83×103M-1.s-1 | 9.62×10-3s-1 | 5.26×10-6M |
嵌合12G4 | 6.49×103M-1.s-1 | 1.53×10-3s-1 | 2.35×10-7M |
鼠类12G4 | 1.47×10-3s-1 | 10-7M的数量级 |
鼠类12G4 | 3C23 | 6B78 | 3C23K | |
KD(nM) | 15.41+/-0.97 | 7.33+/-0.44 | 6.68+/-0.21 | 5.30+/-0.38 |
测量日 | 15 | 21 | 25 | 30 | 32 |
T/C% | 108 | 60 | 42 | 22 | 13 |
测量日 | 12 | 17 | 24 | 27 | 31 | 35 |
T/C% | 101 | 33 | 8 | 8 | 7 | 6 |
测量日 | 33 | 38 | 42 | 47 | 52 |
T/C% | 92 | 38 | 26 | 22 | 21 |
Claims (31)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1053712A FR2959994B1 (fr) | 2010-05-12 | 2010-05-12 | Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii |
FR1053712 | 2010-05-12 | ||
PCT/FR2011/050745 WO2011141653A1 (fr) | 2010-05-12 | 2011-04-01 | Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103119059A true CN103119059A (zh) | 2013-05-22 |
CN103119059B CN103119059B (zh) | 2016-06-29 |
Family
ID=43413855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180032211.8A Active CN103119059B (zh) | 2010-05-12 | 2011-04-01 | 针对人抗苗勒管激素ii型受体的新的突变型人源化12g4抗体及其片段 |
Country Status (11)
Country | Link |
---|---|
US (2) | US9012607B2 (zh) |
EP (1) | EP2569333B1 (zh) |
JP (2) | JP6043998B2 (zh) |
CN (1) | CN103119059B (zh) |
AR (1) | AR081159A1 (zh) |
BR (1) | BR112012028859B1 (zh) |
CA (1) | CA2798336C (zh) |
DK (1) | DK2569333T3 (zh) |
ES (1) | ES2661080T3 (zh) |
FR (1) | FR2959994B1 (zh) |
WO (1) | WO2011141653A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111108123A (zh) * | 2017-05-29 | 2020-05-05 | 加马玛布斯制药公司 | 癌症相关的免疫抑制抑制剂 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2737457B1 (en) | 2011-07-26 | 2019-11-20 | United Parcel Service Of America, Inc. | Systems and methods for managing fault codes |
FR2984750B1 (fr) | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |
EP3331569A1 (en) * | 2015-08-07 | 2018-06-13 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
WO2017079303A1 (en) * | 2015-11-02 | 2017-05-11 | The Cleveland Clinic Foundation | Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer |
FR3060394B1 (fr) | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-amhrii |
MX2019012136A (es) * | 2017-04-14 | 2020-07-20 | Gamamabs Pharma | Compuestos de union al receptor de la hormona antimulleriana tipo ii (amhrii) para prevenir o tratar canceres de pulmon. |
BR112019021472A8 (pt) | 2017-04-14 | 2023-05-02 | Inst Curie | Compostos de ligação ao amhrii para prevenção ou tratamento de cânceres |
EP3789401A1 (en) | 2019-09-03 | 2021-03-10 | Gamamabs Pharma | Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers |
EP3812008A1 (en) | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060188440A1 (en) * | 2003-07-08 | 2006-08-24 | Adams Gregory P | Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer |
CN101506358A (zh) * | 2006-05-15 | 2009-08-12 | 免疫医学股份有限公司 | 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物 |
CN101573382A (zh) * | 2006-11-02 | 2009-11-04 | 法国国家健康医学研究院 | 针对人抗苗勒激素ⅱ型受体(amhr-ⅱ)的单克隆抗体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1343531A2 (en) * | 2000-12-21 | 2003-09-17 | McGILL UNIVERSITY | Conjugates of antibodies and anticancer drugs |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
ES2388932T3 (es) * | 2005-12-02 | 2012-10-19 | Genentech, Inc. | Polipéptidos de unión y usos de los mismos |
CA2648718A1 (en) * | 2006-04-07 | 2007-10-18 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
-
2010
- 2010-05-12 FR FR1053712A patent/FR2959994B1/fr active Active
-
2011
- 2011-04-01 US US13/697,575 patent/US9012607B2/en active Active
- 2011-04-01 CN CN201180032211.8A patent/CN103119059B/zh active Active
- 2011-04-01 WO PCT/FR2011/050745 patent/WO2011141653A1/fr active Application Filing
- 2011-04-01 ES ES11718450.7T patent/ES2661080T3/es active Active
- 2011-04-01 AR ARP110101115A patent/AR081159A1/es active IP Right Grant
- 2011-04-01 EP EP11718450.7A patent/EP2569333B1/fr active Active
- 2011-04-01 DK DK11718450.7T patent/DK2569333T3/en active
- 2011-04-01 CA CA2798336A patent/CA2798336C/fr active Active
- 2011-04-01 JP JP2013509591A patent/JP6043998B2/ja active Active
- 2011-04-01 BR BR112012028859-8A patent/BR112012028859B1/pt active IP Right Grant
-
2015
- 2015-03-16 US US14/658,785 patent/US9637544B2/en active Active
-
2016
- 2016-07-26 JP JP2016146495A patent/JP6435295B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060188440A1 (en) * | 2003-07-08 | 2006-08-24 | Adams Gregory P | Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer |
CN101506358A (zh) * | 2006-05-15 | 2009-08-12 | 免疫医学股份有限公司 | 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物 |
CN101573382A (zh) * | 2006-11-02 | 2009-11-04 | 法国国家健康医学研究院 | 针对人抗苗勒激素ⅱ型受体(amhr-ⅱ)的单克隆抗体 |
Non-Patent Citations (3)
Title |
---|
QING-AN YUAN,ET AL.: "Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning", 《CANCER IMMUNOLOL IMMUNOTHER》 * |
V. R. JUA´REZ-GONZA´ LEZ,ET AL.: "Directed Evolution, Phage Display and Combination of Evolved Mutants: A Strategy to Recover the Neutralization Properties of the scFv Version of BCF2 a Neutralizing Monoclonal Antibody Specific to Scorpion Toxin Cn2", 《J.MOL.BIOL.》 * |
张莉莉等: "抗苗勒管激素与卵巢功能", 《中国妇幼健康研究》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111108123A (zh) * | 2017-05-29 | 2020-05-05 | 加马玛布斯制药公司 | 癌症相关的免疫抑制抑制剂 |
Also Published As
Publication number | Publication date |
---|---|
BR112012028859A2 (zh) | 2017-08-15 |
US9012607B2 (en) | 2015-04-21 |
JP6043998B2 (ja) | 2016-12-14 |
FR2959994B1 (fr) | 2012-08-24 |
BR112012028859B1 (pt) | 2022-02-22 |
CN103119059B (zh) | 2016-06-29 |
WO2011141653A1 (fr) | 2011-11-17 |
EP2569333B1 (fr) | 2017-12-13 |
US20150232563A1 (en) | 2015-08-20 |
JP6435295B2 (ja) | 2018-12-05 |
JP2013534408A (ja) | 2013-09-05 |
ES2661080T3 (es) | 2018-03-27 |
FR2959994A1 (fr) | 2011-11-18 |
CA2798336A1 (fr) | 2011-11-17 |
US9637544B2 (en) | 2017-05-02 |
JP2017029139A (ja) | 2017-02-09 |
US20130136743A1 (en) | 2013-05-30 |
EP2569333A1 (fr) | 2013-03-20 |
DK2569333T3 (en) | 2018-03-26 |
BR112012028859A8 (pt) | 2017-12-05 |
CA2798336C (fr) | 2018-08-21 |
AR081159A1 (es) | 2012-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103119059A (zh) | 针对人抗苗勒管激素ii型受体的新的突变型人源化12g4抗体及其片段 | |
JP2022068161A (ja) | 新規抗pd-l1抗体 | |
WO2021063336A1 (zh) | 靶向cldn18.2的抗体及其制备方法和应用 | |
US8119130B2 (en) | Targeted binding agents directed to KDR and uses thereof—035 | |
JP2021531826A (ja) | 栄養膜細胞表面抗原2(trop2)に対する特異的な抗体 | |
JP2020535839A (ja) | Cd47およびpd−l1に特異的な抗体 | |
CN102348722A (zh) | 人cgrp受体结合蛋白 | |
JP2022515487A (ja) | クローディン18.2結合部分およびその利用 | |
WO2021244328A1 (zh) | 一种抗pd-l1和her2的双特异性抗体 | |
US20230071422A1 (en) | ANTI-CD3 and ANTI-CD123 Bispecific Antibody and Use Thereof | |
WO2022152290A1 (en) | Novel anti-gremlin1 antibodies | |
JP2022532173A (ja) | ヒト化抗cd137抗体およびその使用 | |
JP2022514693A (ja) | Muc18に特異的な抗体 | |
EP4182347A2 (en) | Tigit and cd112r blockade | |
JP2023522492A (ja) | ヒトclaudin及びヒトPDL1タンパク質を標的とする二重特異性抗体及びその使用 | |
JP2022514786A (ja) | Muc18に特異的な抗体 | |
CN115521377A (zh) | 人表皮生长因子受体结合分子及其应用 | |
KR20220048028A (ko) | 항-cd19 항체 및 그의 용도 | |
WO2019174637A1 (zh) | 一种针对tim-3的全人源化抗体分子、抗原结合片段及其医药用途 | |
CN114773485B (zh) | 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子 | |
WO2022262749A1 (zh) | 靶向pd1和/或ox40的特异性结合蛋白 | |
CN105017424B (zh) | 一种egfr抗体可变区及其应用 | |
WO2020248156A1 (zh) | Pd-l1靶向结合剂及其用途 | |
WO2023137161A1 (en) | Triple blockade of tigit, cd112r, and pd-l1 | |
TW202337908A (zh) | 抗b7-h7抗體或其抗原結合片段及製備方法與應用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: FRENCH LABORATORY FOR FRACTIONATION AND BIOTECHNOL Free format text: FORMER OWNER: LFB BIOTECHNOLOGIES Effective date: 20140120 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140120 Address after: France Levin foruris Applicant after: French Laboratory For Fractionation and Biotechnology Corp. Applicant after: Universite Montpellier 1 Applicant after: Inst Nat Sante Rech Med Applicant after: National Health and Medicine Inst. Address before: France Levin foruris Applicant before: Univ Montpellier I Applicant before: Universite Montpellier 1 Applicant before: Inst Nat Sante Rech Med Applicant before: National Health and Medicine Inst. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: French pitot Patentee after: LFB BIOTECHNOLOGIES Patentee after: Universite Montpellier I Patentee after: Guo Jiakangaizhongxin Patentee after: INSERM (INSTITUT NATIONAL DE LA SANTe ET DE LA RECHERCHE MeDICALE) Address before: France Levin foruris Patentee before: LFB BIOTECHNOLOGIES Patentee before: Universite Montpellier I Patentee before: Guo Jiakangaizhongxin Patentee before: INSERM (INSTITUT NATIONAL DE LA SANTe ET DE LA RECHERCHE MeDICALE) |